Bispecific Anti-TRAILR2 and Anti-CDH17 Binding Molecules for Cancer Treatment - EP3559040A2

The EPO published European patent application EP3559040A2, filed by Boehringer Ingelheim International GmbH, covering bispecific anti-TRAILR2 and anti-CDH17 binding molecules for cancer treatment. The application claims priority to multiple inventors including Kuenkele, Fenn, Garcia-Martinez, Ho, Koessl, Sen, Voynov, Wernitznig, Eryilmaz, Shaaban, and Ganesan, with IPC classifications spanning antibodies (C07K 16/28), therapeutic proteins (A61K 39/395), antineoplastic agents (A61P 35/00), and recombinant protein sequences (C12N 15/62). The publication kind A2 indicates this is a published international application pending before the EPO.

For pharmaceutical and biotechnology companies, this patent publication signals Boehringer Ingelheim's strategic positioning in bispecific antibody therapeutics targeting dual tumor-associated antigens. Competitors developing similar bispecific formats or targeting TRAILR2/CDH17 pathways should review the claims upon grant to assess freedom-to-operate implications. The A2 publication status means the application has entered the European regional phase and will undergo substantive examination before potential grant.